Around 100 million people worldwide suffer from chronic wounds that fail to heal properly. Among the most challenging conditions to treat are diabetic foot ulcers (DFUs).
Often referred to as a “silent killer,” DFUs have five-year mortality rates and treatment costs comparable to those of cancer. Within five years of diagnosis, 30.5% of DFU patients die.
For patients who undergo major amputations, more than half do not survive beyond five years.
Estonian MedTech company Nanordica Medical has successfully raised €1.6 million in funding to support the launch of its innovative nanotechnology-based wound dressing, designed to accelerate the healing of chronic wounds.
As one of the largest clinical trials in the field approaches completion, Nanordica is preparing to introduce its Premotiv® wound dressing to patients across Europe in 2026, followed by entry into the U.S. market in 2027.
Nanordica Medical is an Estonian medical technology company and a pioneer in advanced antibacterial nanotechnology for the prevention and treatment of topical bacterial infections.
The company is a spin-off from the National Institute of Chemical Physics and Biophysics in Estonia, translating cutting-edge scientific research into innovative healthcare solutions.
Nanordica Medical was nominated as HealthTech of the Year 2025 at the Estonian Startup Awards.
11.06.2026.
